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Abstract
Diesel exhaust particles (DEPs) are common environmental air pollutants primarily affecting
the lung. DEPs or chemicals adsorbed on DEPs also exert extra-pulmonary effects, includ-
ing alteration of hepatic drug detoxifying enzyme expression. The present study was de-
signed to determine whether organic DEP extract (DEPe) may target hepatic drug
transporters that contribute in a major way to drug detoxification. Using primary human he-
patocytes and transporter-overexpressing cells, DEPe was first shown to strongly inhibit ac-
tivities of the sinusoidal solute carrier (SLC) uptake transporters organic anion-transporting
polypeptides (OATP) 1B1, 1B3 and 2B1 and of the canalicular ATP-binding cassette (ABC)
efflux pump multidrug resistance-associated protein 2, with IC50 values ranging from ap-
proximately 1 to 20 μg/mL and relevant to environmental exposure situations. By contrast,
25 μg/mL DEPe failed to alter activities of the SLC transporter organic cation transporter
(OCT) 1 and of the ABC efflux pumps P-glycoprotein and bile salt export pump (BSEP),
whereas it only moderately inhibited those of sodium taurocholate co-transporting polypep-
tide and of breast cancer resistance protein (BCRP). Treatment by 25 μg/mL DEPe was
next demonstrated to induce expression of BCRP at both mRNA and protein level in cul-
tured human hepatic cells, whereas it concomitantly repressed mRNA expression of various
transporters, including OATP1B3, OATP2B1, OCT1 and BSEP. Such changes in transport-
er expression were found to be highly correlated to those caused by 2,3,7,8-tetrachlorodi-
benzo-p-dioxin (TCDD), a reference activator of the aryl hydrocarbon receptor (AhR)
pathway. This suggests that DEPe, which is enriched in known ligands of AhR like polycy-
clic aromatic hydrocarbons, alters drug transporter expression via activation of the AhR cas-
cade. Taken together, these data established human hepatic transporters as targets of
organic chemicals containing in DEPs, which may contribute to their systemic effects
through impairing hepatic transport of endogenous compound or drug substrates of
these transporters.
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Introduction
Diesel exhaust particles (DEPs) are major and widely-distributed environmental air pollutants,
originating from diesel engines [1]. They are usually composed of a center core of elemental
carbon and adsorbed organic compounds, including polycyclic aromatic hydrocarbons
(PAHs) and nitro-PAHs, and small amounts of sulfate, nitrate, metals, and other trace ele-
ments. They have sizes generally less than 1 μm and, as such, represent a mixture of fine (diam-
eter below 2.5 μm), ultrafine (diameter below 100 nm) and nano particles (diameter below
50 nm) [2]. Human exposure to these DEPs is very frequent, especially in urban areas [3], and
is thought to promote airway inflammation, asthma, cardiopulmonary diseases and lung can-
cer [4–6].
Even if toxic effects of DEPs primarily target the lung, thus reflecting that the major, if not
exclusive, way of exposure to these pollutants is inhalation, systemic effects, including vascular
and inflammatory effects, also occur [7–9]. This may be consistent with the passage across the
pulmonary alveolar-capillary barrier of ultrafine DEPs [10] and/or of some organic or inorgan-
ic compounds primarily adsorbed on DEPs such as PAHs [11]. In this context, exposure to
DEPs has been demonstrated to affect the liver, notably causing fatty changes, accumulation of
lipid peroxidation products, activation of the leukotrienes-producing 5-lipoxygenase pathway
and up-regulation of inflammatory cytokines [12, 13]. The drug metabolizing enzymes cyto-
chrome P-450 (CYP) 1A1 and CYP1B1 and the antioxidant enzyme NAD(P)H-quinone oxi-
doreductase 1 are also induced in hepatic cells exposed to DEP extract (DEPe) and in the liver
of rodents exposed to DEPs [14–16]. Such data indicate that these pollutants, like other inhaled
deleterious contaminants such as cigarette smoke [17, 18], may alter hepatic detoxification
pathways, probably through activation of the aryl hydrocarbon receptor (AhR) pathway [19].
It is noteworthy that hepatic drug detoxifying pathways implicate not only enzymes like
CYPs, but also membrane drug transporters [20]. These transporters, that belong to the solute
carrier (SLC) or the ATP-binding cassette (ABC) transporter families, mediate uptake of drugs
at the sinusoidal pole of hepatocytes and their efflux into the bile at the canalicular pole [21].
Some of them, especially the ABC transporter P-glycoprotein (ABCB1) and the breast cancer
resistance protein (BCRP/ABCG2), have been shown to be regulated by inhalable chemical
contaminants, including cigarette smoke extract [22] and PAHs [23–25]. In the same way,
DEPs have been shown to induce expression of P-glycoprotein, BCRP and multidrug resis-
tance-associated protein (MRP) 2 (ABCC2) at the blood-brain barrier [26]. By contrast, wheth-
er DEP-adsorbed chemicals may affect activity and/or expression of hepatic drug transporters
remains unknown. The present study was therefore designed to get insights about this point.
Our data demonstrate that organic DEPe markedly inhibited activity of organic anion-trans-
porting polypeptides (OATPs/SLCOs) and of MRP2 and induced BCRP expression in cultured
human hepatocytes and hepatocyte-like cells. Such changes may contribute to systemic effects
of DEPs through impairing hepatic transport of endogenous compounds or drugs substrates of
these transporters.
Materials and Methods
Chemicals
DEPe used in the study was the Standard Reference Material 1975 (SRM 1975), purchased
by the National Institute of Standards and Technology (NIST) (Gaithersburg, MD, USA). It
corresponds to a dichloromethane extract of filter-collected combustion particulate matter
from operating forklifts with diesel engines [27]; some of its chemical components have
been characterized in the certificate of analysis provided by NIST [28]. Dichloromethane
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was evaporated under nitrogen and the final residue was dissolved in dimethyl sulfoxide
(DMSO) for cell exposure. Final concentration of DMSO did not exceed 0.2% (vol/vol); control
cultures received the same dose of solvent as for treated counterparts. Verapamil, probenecid,
fumitremorgin C, bromosulfophtalein, fluorescein, fluoranthene, phenanthrene, benzo[b]
fluoranthene, chrysene, 1-nitropyrene and 1,2-naphtoquinone were provided by Sigma-Al-
drich (Saint-Quentin Fallavier, France), whereas carboxy-2,7-dichlorofluorescein (CF) diace-
tate and Hoechst 33342 were from Life Technologies (Saint Aubin, France) and 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) from Cambridge Isotope Laboratories (Cambridge,
MA). [3H(G)] taurocholic acid (sp. act. 1.19 Ci/mmol), [6,7-3H(N)] estrone-3-sulfate (E3S)
(sp. act. 57.3 Ci/mmol) and [1–14C] tetra-ethylammonium (TEA) (sp. act. 2.4 mCi/mmol)
were from Perkin-Elmer (Boston, MA). All other chemicals were commercial products of the
highest purity available.
Cell culture
Human hepatocyte suspensions were provided by the Biological Resource Center (University
Hospital, Rennes, France), which has obtained the authorization N°DC-2008-630 from the
French Ministry of Health to collect hepatic resections from the digestive surgery department
and then to isolate and deliver the hepatocytes used in this study. All of liver fragment donors
provided a written informed consent to participate in the study. Basic information related to
liver fragment donors, including age, sex and type of disease, was collected by the Biological
Resource Center and is available. The authors did not interact with the donors of hepatocytes
and have no direct access to their clinical and biological data. Hepatocytes, initially prepared
by enzymatic dissociation of histologically-normal liver fragments [29], were seeded on plastic
dishes at a density of 2 × 105 cells/cm2 in Williams' E medium (Invitrogen, Cergy-Pontoise,
France), supplemented with 10% (vol/vol) fetal calf serum (Perbio Sciences, Brébieres, France),
5 μg/mL bovine insulin (Sigma-Aldrich), 100 IU/mL penicillin, 100 μg/mL streptomycin, and
2 mM glutamine (Invitrogen). After 24 h, this seeding medium was discarded, and primary he-
patocytes were routinely cultured in the fetal calf serum-containing Williams' E medium de-
fined above and supplemented with 5 × 10−5 M hydrocortisone hemisuccinate (Upjohn, Paris
La Défense, France) and 2% (vol/vol) DMSO, as reported previously [30]. All experimental
procedures complied with French laws and regulations and were approved by the National
Ethics Committee.
Human highly-differentiated hepatoma HepaRG cells, which are well-recognized as surro-
gates for human hepatocytes in drug detoxification pathway studies [31], were routinely cul-
tured in Williams' E medium (Life Technologies) supplemented with 10% (vol/vol) fetal calf
serum, 100 IU/mL penicillin, 100 μg/mL streptomycin, 5 μg/mL insulin, 2 mM glutamine, and
5 x 10−5 M hydrocortisone hemisuccinate. Additional culture for two weeks in the same medi-
um supplemented with 2% (vol/vol) DMSO was performed in order to get a full hepatocytic
differentiation of the cells [32].
P-glycoprotein-overexpressing mammary MCF-7/R cells [33] and MRP2-expressing
human hepatoma HuH-7 cells [34] were cultured in Dulbecco’s modified Eagle medium
(DMEM) (Life Technologies), supplemented with 10% (vol/vol) fetal calf serum, 100 IU/mL
penicillin and 100 μg/mL streptomycin. BCRP-transfected HEK 293 cells [35], kindly donated
by Dr X. Decleves (Faculty of Pharmacy, University Paris-Descartes, Paris, France), were cul-
tured in DMEM supplemented with 10% (vol/vol) fetal calf serum, 100 IU/mL amoxicillin,
100 μg/mL erythromycin and 200 μg/mL G418. OATP1B1 (SLCO1B1)-, OATP1B3 (SLCO1B3)-
and OATP2B1 (SLCO2B1)-transfected CHO cells were cultured in DMEM containing
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100 IU/mL penicillin, 100 μg/mL streptomycin, 10% (vol/vol) fetal calf serum and 500 μg/mL
G418, as previously reported [36].
Transporter activity assays
Uptake SLC transporter activity. The effects of DEPe on sodium taurocholate co-trans-
porting polypeptide (NTCP/SLC10A1), OATP and organic cation transporter (OCT) 1
(SLC22A1) activities were analysed through determining intracellular accumulation of refer-
ence substrates of these sinusoidal influx transporters using a well-defined transport medium
[37]. Briefly, for NTCP activity, cells were incubated at 37°C with 43.4 nM [3H] taurocholate
for 10 min, in the absence or presence of sodium or DEPe; for OATP activity, cells were incu-
bated at 37°C for 6 min with 3.4 nM [3H] E3S or 10 μM fluorescein, in the absence or presence
of DEPe or reference OATP inhibitors (probenecid or bromosulfophtalein) [38, 39]; for OCT1
activity, HepaRG cells were incubated at 37°C with 40 μM [14C] TEA for 5 min, in the absence
or presence of DEPe or a reference OCT1 inhibitor (verapamil) [40]. After washing in phos-
phate-buffered saline (PBS), cells were lysed and accumulation of substrates was determined
through scintillation counting (for taurocholate, E3S and TEA) or through spectrofluorimetry
(for fluorescein) using a SpectraMax Gemini SX spectrofluorometer (Molecular Devices, Sun-
nyvale, CA) (Excitation and emission wavelengths were 485 and 535 nm, respectively). Data
were expressed as amount of intracellular substrate/mg protein. For OATPs, data were also ex-
pressed as % of E3S uptake found in control cells or as % of OATP activity, according to the fol-
lowing equation:
%OATP activity ¼ ðAccumulationDEPe  AccumulationReference inhibitorÞ  100
AccumulationControl AccumulationReference inhibitor
with AccumulationDEPe = substrate accumulation in the presence of DEPe, AccumulationControl =
substrate accumulation in control cells, AccumulationReference inhibitor = substrate accumulation in
the presence of a reference OATP inhibitor.
Efflux ABC transporter activity. The effects of DEPe on P-glycoprotein activity were ana-
lysed in P-glycoprotein-expressing MCF-7/R cells, through measuring intracellular accumula-
tion of the P-glycoprotein substrate rhodamine 123 [41]. Briefly, MCF-7/R cells were
incubated at 37°C with 5.25 μM rhodamine 123 for 30 min, in the presence or absence of DEPe
or a reference P-glycoprotein inhibitor (verapamil) [42]. After washing in PBS, cells were lysed
and intracellular accumulation of rhodamine 123 was determined by spectrofluorimetry (Exci-
tation and emission wavelengths were 485 and 535 nm, respectively). Data were expressed as %
of rhodamine 123 accumulation in control cells.
The effects of DEPe on MRP2 activity were analysed in MRP2-expressing HuH-7 cells,
through measuring intracellular accumulation of the MRP2 substrate CF [43]. Briefly, HuH-7
cells were incubated at 37°C with 3 μMCF diacetate for 30 min, in the presence or absence of
DEPe or a reference MRP2 inhibitor (probenecid) [43]. Intracellular accumulation of CF was
determined by spectrofluorimetry as reported above. Data were expressed as % of CF accumu-
lation in control cells or as % of MRP2 activity according to the following equation:
%MRP2 activity ¼ ðAccumulationReference inhitor  AccumulationDEPeÞ  100
AccumulationReference inhibitor  AccumulationControl
with AccumulationDEPe = CF accumulation in the presence of DEPe, AccumulationControl = CF
accumulation in control cells, AccumulationReference inhibitor = CF accumulation in the presence
of a reference MRP2 inhibitor.
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The effects of DEPe on BCRP activity were determined in BCRP-HEK 293 cells through
measuring intracellular retention of the BCRP substrate Hoechst 33342 [44]. Briefly, BCRP-
HEK 293 cells were first loaded at 37°C with 16.2 μMHoechst 33342 for 30 min. After washing
in PBS, cells were re-incubated in Hoechst 33342-free medium at 37°C for 90 min in the ab-
sence or presence of DEPe or 10 μM fumitremorgin C, used here as a reference inhibitor for
BCRP [45]. Intracellular retention of Hoechst 33342 was determined by spectrofluorimetry as
described above (Excitation and emission wavelengths were 355 and 460 nm, respectively).
Data were expressed as % of initial Hoechst 33342 loading.
The effects of DEPe on bile salt export pump (BSEP/ABCB11) activity were analysed in pri-
mary human hepatocytes, through measuring BSEP-mediated secretion of taurocholate into bile
canaliculi-like structures as previously reported [46]. Briefly, hepatocytes were first incubated for
10 min at 37°C with transport assay buffer containing Ca2+ or with the same buffer, except that
1.8 mMCaCl2 was withdrawn and 100 μMEGTAwas added; incubation with this Ca
2+-free
buffer promotes disruption of tight junctions and opening of bile canaliculi networks [46]. Buff-
ers were then removed and hepatocytes were further incubated for 10 min at 37°C in transport
assay medium containing 43.4 nM [3H] taurocholate in the absence or presence of DEPe. After
washing with PBS, accumulations of taurocholate into cells + bile canaliculi (Ca2+-containing
conditions) and into cells only (Ca2+-free conditions) were determined by scintillation counting.
Biliary excretion index (BEI) reflecting canalicular secretion of taurocholate was calculated using
the following equation [47]:
BEI ¼ Accumulation ðCellsþ Bile canaliculiÞ  Accumulation ðCellsÞ
Accumulation ðCellsþ Bile canaliculiÞ  100
Protein concentration determination
Protein concentration in cell samples was determined using the Bradford assay as previously
described [48].
RNA isolation and analysis
Total RNAs were extracted using the TRI reagent (Sigma-Aldrich). RNA was then subjected to
reverse transcription-quantitative polymerase chain reaction (RT-qPCR), using the RT kit
from Applied Biosystems (Foster City, CA), the fluorescent dye SYBR Green methodology and
an ABI Prism 7300 detector (Applied Biosystems), as previously described [49]. Gene-specific
primers for drug transporters, CYP1A1, CYP1B1, aldehyde deshydrogenase 3A1 (ALDH3A1)
and 18S RNA were used exactly as previously reported [49–51]. The specificity of each gene
amplification was verified at the end of qPCR reactions through analysis of dissociation curves
of the PCR products. Amplification curves were analysed with ABI Prism 7000 SDS software,
using the comparative cycle threshold method. Relative quantification of the steady-state target
mRNA levels was calculated after normalization of the total amount of cDNA tested to the 18S
RNA endogenous reference using the 2(−ΔCt) method. Data were finally expressed as % of val-
ues found in untreated control cells or in arbitrary units relative to 18S RNA content as previ-
ously described [52].
Western-blot analysis
Crude membrane extracts were prepared as previously reported [53]. Proteins were then sepa-
rated on SDS polyacrylamide gels and electrophoretically transferred to nitrocellulose
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membranes. After blocking in Tris-buffered saline containing 4% bovine serum albumin,
membranes were incubated overnight at 4°C with primary antibodies directed against
OATP1B1, OATP2B1 [54], P-glycoprotein, BCRP (Alexis Biochemicals, Lausen, Switzerland),
MRP2 or MRP3 (Millipore Bioscience Research Reagents, Temecula, CA). Peroxidase-conju-
gated monoclonal antibodies were thereafter used as secondary antibodies. After washing,
immuno-labelled proteins were visualized by chemiluminescence. Gel loading and transfer was
checked up by staining membranes with Ponceau red [55]. Intensities of antibody-stained
bands and Ponceau red-stained lanes were measured by densitometry using ImageJ 1.40g soft-
ware (National Institute of Health, Besthesda, MA), allowing to normalise antibody-related
staining to Ponceau red-labeling.
Calculation of PAH concentrations in DEPe solutions
PAH concentrations in DEP solutions were calculated from mass fractions for selected PAHs
reported in SRM 1975, according to the following equation:
½PAH ¼ ðMass fractionPAH  ½DEPeÞ  1000
Molecular weightPAH
Statistical analysis
Quantitative data were usually expressed as means ± SEM. They were statistically analysed
using ANOVA followed by a Dunnett’s post-hoc test, Student’s t-test or nonparametric Spear-
man’s rank correlation method. The criterion of significance was p< 0.05. Half maximal inhib-
itory concentration (IC50) values were determined using GraphPad Prism software (GraphPad
Software, La Jolla, CA), through nonlinear regression based on the four parameter
logistic function.
Results
Effects of DEPe on hepatic SLC transporter activity
The potential direct effects of DEPe on uptake SLC drug transporter activities were first ana-
lysed in primary human hepatocytes. For this purpose, DEPe was added at a 25 μg/mL concen-
tration, that likely corresponds to a 4.92 μg/cm2 equivalent DEP dose according to previous
conversions of in vitro DEPe/DEP dose to DEP dose/unit surface area [56] and that is in the
range of DEPe/DEP concentrations commonly retained for in vitro studies [57–59]. As shown
in Fig. 1A, addition of DEPe was found to significantly, but rather moderately, decrease uptake
of the NTCP substrate taurocholate in primary human hepatocytes; by contrast, withdrawal of
sodium nearly fully blocked taurocholate accumulation, in agreement with the sodium-depen-
dence of taurocholate transport by NTCP [60]. In contrast to the reference OCT1 inhibitor ve-
rapamil [40], DEPe failed to alter uptake of the OCT1 substrate TEA in primary human
hepatocytes (Fig. 1A). DEPe, as well as the reference OATP inhibitor probenecid [38], was next
shown to strongly inhibit uptake of the OATP substrate E3S. This inhibition of OATP activity
in primary human hepatocytes by DEPe was concentration-dependent, with a DEPe IC50 value
of 6.7 ± 1.1 μg/mL (Fig. 1B).
Because human hepatocytes express several OATP transporters at their sinusoidal pole, i.e.,
OATP1B1, OATP1B3 and OATP2B1 [21], we investigated whether these different OATPs
were directly inhibited by DEPe using OATP-transfected CHO cells and E3S as a reference
substrate for OATP1B1 and OAPTP2B1 [61] and fluorescein as a reference substrate for
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Fig 1. Effects of DEPe on NTCP, OATP and OCT1 transport activity in primary human hepatocytes. (A) NTCP-mediated uptake of taurocholate,
OATPs-mediated uptake of E3S and OCT1-mediated uptake of TEA in primary human hepatocytes were determined in the absence or presence of 25 μg/mL
DEPe as reported in the Material and Methods. Reference inhibition of NTCP, OATP and OCT1 activity was obtained in parallel through withdrawal of sodium
(NTCP inhibition) or addition of 2 mM probenecid (OATP inhibition) or of 50 μM verapamil (OCT1 inhibition). Data are expressed as substrate accumulation/
mg protein and are the means ± SEM of at least three independent experiments. *, p<0.05 when compared to control cells (ANOVA followed by a Dunnett’s
post-hoc test). (B) OATPs-mediated transport of E3S was measured in the absence or presence of various concentrations of DEPe (from 0.1 to 50 μg/mL) or
Drug Transporter Regulation by Diesel Particle Extract
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OATP1B3 [62]. As shown in Fig. 2, DEPe blocked transport of E3S by both OATP1B1 and
OATP2B1 in a concentration-dependent manner, OATP1B1 being more sensitive to the inhib-
itory effects of DEPe than OATP2B1 (IC50 were 1.1 ± 0.3 μg/mL and 4.3 ± 1.2 μg/mL, for
OATP1B1 and OATP2B1, respectively). DEPe also inhibited OATP1B3-mediated transport of
fluorescein, with a higher IC50 (20.5 ± 1.2 μg/mL) than those reported above for the inhibition
of OATP1B1- and OATP2B1-mediated transport of E3S (Fig. 2).
Effects of DEPe on ABC transporter activity
The potential direct effects of DEPe on ABC drug transporter activities were analysed in ABC-
transporter overexpressing cells (for P-glycoprotein, MRP2 and BCRP) and in primary human
hepatocytes (for BSEP). As shown in Fig. 3A, 25 μg/mL DEPe failed to induce accumulation of
the P-glycoprotein substrate rhodamine 123 in P-glycoprotein-overexpressing MCF7/R cells,
in contrast to the reference P-glycoprotein inhibitor verapamil [42]. Such data most likely indi-
cate that DEPe did not inhibit P-glycoprotein-mediated efflux of rhodamine 123. DEPe was
found to enhance retention of the BCRP substrate Hoechst 33342 in BCRP-transfected HEK
293 cells. This increase was however lower than that triggered by the reference BCRP inhibitor
fumitremorgin C and DEPe failed to fully prevent loss of the dye during the efflux period
(Fig. 3A), thus suggesting that DEPe altered BCRP-mediated efflux of the dye in a rather mod-
erate manner. By contrast, DEPe (25 μg/mL) markedly induced accumulation of CF in MRP2-
expressing HuH-7 cells by a 3.5-fold factor (Fig. 3A); the reference MRP2 inhibitor probenecid
also similarly increased CF accumulation. Such data indicated that DEPe was able to strongly
block MRP2-mediated efflux of CF. This inhibitory effect of DEPe towards MRP2 activity was
moreover demonstrated to be concentration-dependent, with an IC50 value of 5.8 ± 1.1 μg/mL
(Fig. 3B). The effects of DEPe on BSEP-mediated canalicular secretion of taurocholate was
characterized through determining BEI for taurocholate in primary human hepatocytes
(Fig. 3C). Similar BEI values, around 60%, were found in control and DEPe-exposed hepato-
cytes, thus likely indicating that DEPe failed to impair BSEP activity.
Effects of DEPe-containing chemicals on OATP1B1 and MRP2 activity
Previous chemical characterization of DEPe used in the present study has revealed the presence
of various PAHs and nitro-PAHs as main components of DEPe, as indicated by the certificate
of analysis provided by NIST [28]. Because some PAHs, including PAH metabolites, have been
shown to interfere with drug transporters, especially MRP2 [63], we wondered whether these
compounds may be involved in DEPe-mediated inhibition of OATP1B1 and MRP2 activity.
For such a purpose, we focused on some PAHs among the most concentrated ones present in
DEPe, such as phenanthrene, fluoranthene, benzo[b]fluoranthene, chrysene and 1-nitropyrene
[28]. The concentrations of these PAHs in DEPe solutions inhibiting 50% of OATP1B1 (Fig. 2)
or MRP2 (Fig. 3B) activity were calculated from concentrations reported in native DEPe [28]
and are indicated in Table 1. None of these PAHs, used at a 10 μM concentration much higher
than those calculated in IC50-based DEPe solutions (that are in the 0.01–0.5 nM range, as
shown in Table 1), was found to inhibit E3S accumulation in OATP1B1-transfected HEK 293
cells (Fig. 4A) or to enhance CF accumulation in MRP2-expressing HuH-7 cells (Fig. 4B), indi-
cating a lack of inhibition of OATP1B1 or MRP2. The PAH derivative 1,2-naphtoquinone,
of the reference OATP inhibitor probenecid. Data are expressed as % of OATP activity calculated as described in Materials and Methods and are the
means ± SEM of five independent assays. DEPe IC50 value is indicated at the top of the graph.
doi:10.1371/journal.pone.0121232.g001
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Fig 2. Concentration-dependent inhibition of OATP1B1, OATP1B3 and OATP2B1 activity by DEPe.
OATP1B1- and OATP2B1-mediated transport of E3S and OATP1B3-mediated transport of fluorescein were
determined in OATP-transfected CHO cells in the absence or presence of various concentrations of DEPs
(from 0.1 to 50 μg/mL) or of the reference inhibitors 100 μM bromosulfophtalein (for OATP1B1 and
OATP2B1) or 10 mM probenecid (for OATP1B3). Data are expressed as % of OATP activity calculated as
described in Materials and Methods and are the means ± SEM of three independent assays. DEPe IC50
values are indicated at the top of the graphs.
doi:10.1371/journal.pone.0121232.g002
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Fig 3. Effects of DEPe on P-glycoprotein, BCRP, MRP2 and BSEP transport activity. (A) P-glycoprotein, BCRP and MRP2 activities were determined
through measurement of rhodamine 123 accumulation, Hoechst 33342 retention and CF accumulation in transporter-expressing cell lines in the absence or
presence of 25 μg/mL DEPe as reported in the Material and Methods. Reference inhibition of transporter activity was obtained in parallel through addition of
50 μM verapamil (P-glycoprotein inhibition), 10 μM fumitremorgin C (FTC) (BCRP inhibition) or 10 mM probenecid (OATP inhibition). Data are expressed as
% of dye accumulation (P-glycoprotein and MRP2 activities) or dye retention (BCRP activity) in control untreated cells; they are the means ± SEM of at least
three independent experiments. *, p<0.05 when compared to control cells (ANOVA followed by a Dunnett’s post-hoc test). (B) CF accumulation was
measured in HuH-7 cells in the absence or presence of various concentrations of DEPe (from 0.1 to 50 μg/mL) or of the reference OATP inhibitor probenecid.
Data are expressed as % of MRP2 activity calculated as described in Materials and Methods and are the means ± SEM of four independent assays. DEPe
IC50 value is indicated at the top of the graph. (C) BEI for taurocholate, reflecting BSEP activity, was determined in primary human hepatocytes in the
absence or presence of 25 μg/mL DEPe, as reported in Materials and Methods. Data are the means ± SEM of three independent experiments. NS, not
significant (Student’s t-test).
doi:10.1371/journal.pone.0121232.g003
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whose presence has been reported in DEPs at a significant level [64], also failed to alter
OATP1B1- and MRP2-related transport (Fig. 4A and Fig. 4B).
Effects of DEPe on drug transporter expression
Human hepatoma HepaRG cells, that have been demonstrated to represent a convenient alter-
native to the use of primary human hepatocytes for transporter regulation studies [31, 65],
were first exposed to various concentrations of DEPe (from 10 μg/mL to 50 μg/mL) for 48 h.
Such treatments did not trigger any obvious toxicity in HepaRG cells as shown by light micro-
scopic analysis and iodure propidium/Hoechst 33342 labeling of necrotic/apoptotic cells
(data not shown). DEPe exposure increased mRNA expression of CYP1A1, a known reference
target for DEPs (58). The induction was dose-dependent, i.e., it was higher for the DEPe con-
centrations of 25 μg/mL and 50 μg/mL than that for 10 μg/mL DEPe (Fig. 5A). DEPe used at
25 μg/mL was shown to similarly induce CYP1A1 expression for a 48 h-72 h treatment time;
a shorter exposure time (24 h) was less active (Fig. 5A). The dose of 25 μg/mL DEPe and a
treatment time of 48 h were consequently retained for analyzing the effects of DEPe on hepatic
drug transporter expression. As shown in Fig. 5B, such an exposure to DEPe of HepaRG cells
resulted in a down-regulation of mRNA expression of various SLC drug transporters including
OATP1B3, OATP2B1, organic anion transporter 2 (OAT2/SCL22A7), OCT1 and NTCP. Re-
pression fold-factors, i.e., the ratio expression in untreated control cells versus expression in
DEPe-exposed cells, ranged from 1.42 (for OAT2) to 1.63 (for OCT1) and were rather moder-
ate. The ABC efflux pump BSEP was also repressed by DEPe exposure, by a 2.21-fold factor
(Fig. 5B). By contrast, MRP3 and BCRP mRNA levels were significantly induced by DEPe
treatment, by 1.37- and 1.66-fold factors, respectively, whereas OATP1B1, MDR1 and MRP2
mRNA expression remained unchanged (Fig. 5B).
Western-blot analysis indicated that BCRP protein expression was significantly induced by
a 2.44-fold factor by DEPe treatment in HepaRG cells (Fig. 6A). DEPe also induced BCRP ex-
pression in two independent populations of primary human hepatocytes (Fig. 6B). DEPe
slightly increased protein expression of MRP2 and MRP3 by 1.45- and 1.47-fold factors, re-
spectively, in HepaRG cells, but such inductions failed to reach a significant level (Fig. 6A). By
contrast, DEPe failed to obviously alter expression of OATP1B1, OATP2B1 and P-glycopro-
tein/MDR1 (Fig. 6A).
The fact that DEPe induced mRNA expression of CYP1A1, a reference target of the AhR
pathway, indicated that this signaling way was activated by DEPe in HepaRG cells, as expected
owing to the well-established presence of AhR agonists such as PAHs in DEPe [19]. This
Table 1. Concentrations of selected PAHs in native DEPe and DEPe solutions.
PAH Molecular weight PAH concentration
Native DEPea DEPe solution
1.1 μg/mL (IC50/OATP1B1) 5.8 μg/mL (IC50/MRP2)
Phenanthrene 178.2 g 8.00 mg/kg 0.049 nM 0.26 nM
Fluoranthene 202.26 g 13.5 mg/kg 0.073 nM 0.39 nM
Benzo[b]fluoranthene 252.31 g 3.20 mg/kg 0.014 nM 0.073 nM
Chrysene 228.9 g 1.95 mg/kg 0.009 nM 0.050 nM
1-Nitropyrene 247.25 g 16.59 mg/kg 0.074 nM 0.39 nM
aData for native DEPe are fraction mass reported in the certificate of analysis for SRM 1975 provided by NIST [28]
doi:10.1371/journal.pone.0121232.t001
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Fig 4. Effects of various DEPe-contained PAHs on OATP1B1 and MRP2 activity. (A) OATP1B1-
mediated transport of E3S was determined in OATP1B1-transfected CHO cells in the absence or presence of
the reference OATP inhibitor bromosulfophtalein (BSP) (100 μM) or of various DEPe-contained PAHs or PAH
derivatives, each being used at 10 μM. Data are expressed as % of E3S accumulation in control untreated
cells and are the means ± SEM of three independent assays. *, p<0.05 when compared to control cells
(ANOVA followed by a Dunnett’s post-hoc test). (B) Accumulation of the MRP2 substrate CF was measured
in HuH-7 cells in the absence or presence of DEPe (25 μg/mL) or of various DEPe-contained PAHs or PAH
derivatives, each being used at 10 μM. Data are expressed as % of CF accumulation in control untreated
cells and are the means ± SEM of three independent assays. *, p<0.05 when compared to control cells
(ANOVA followed by a Dunnett’s post-hoc test).
doi:10.1371/journal.pone.0121232.g004
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conclusion is supported by the fact that exposure to DEPe resulted in up-regulation of CYP1B1
and ALDH3A1 (S1 Fig.), two other well-known reference markers regulated by the AhR path-
way [51]. Because AhR has been involved in regulation of some transporters [24, 66], its impli-
cation in DEPe-mediated regulation of drug transporters has to be considered. In this context,
the exact impact of AhR activation on drug transporter expression in HepaRG cells was charac-
terized using TCDD, a potent reference agonist of AhR, whose effects are presumed to be strict-
ly dependent on AhR [67]. Treatment by 10 nM TCDD of HepaRG cells for 48 h induced
Fig 5. Regulation of drug transporter mRNA expression by DEPe. (A) Human highly-differentiated
HepaRG cells were either untreated or exposed to various concentrations of DEPe for 48 h (right panel) or to
25 μg/mL DEPe for various exposure time (left panel). CYP1A1 mRNA expression was analysed by RT-
qPCR. Data are expressed in arbitrary units relative to 18S RNA content and are the means ± SEM of three
independent assays. *, p<0.05 when compared to control cells (ANOVA followed by a Dunnett’s post-hoc
test). (B) HepaRG cells were either untreated or exposed to 25 μg/mL DEPe for 48 h. Drug transporter mRNA
expression was evaluated by RT-qPCR. Data are expressed as % of transporter expression found in control
untreated cells, arbitrary set at 100% and indicated by a dotted line; they are the means ± SEM of three
independent assays. *, p<0.05 when compared to control cells (ANOVA followed by a Dunnett’s post-hoc
test).
doi:10.1371/journal.pone.0121232.g005
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CYP1A1, CYP1B1 and ALDH3A1 mRNA expression (S2 Fig.), indicating that the AhR signal-
ing pathway was activated by TCDD in HepaRG cells. With respect to transporter mRNA lev-
els, TCDD induced those of BCRP and MRP3 and repressed those of OATP2B1, NTCP, OCT1
and BSEP in HepaRG cells (Fig. 7A). This transporter expression profile caused by TCDD-me-
diated AhR activation was next compared to that resulting from DEPe exposure. For such a
purpose, transporters were ranked from the most induced to the most repressed according to
their mRNA expression level and potential correlation between TCDD and DEPe treatment
with respect to drug transporter regulation was analysed using the Spearman's rank correlation
Fig 6. Regulation of drug transporter protein expression by DEPe. (A) HepaRG cells were either
untreated (control) or exposed to 25 μg/mL DEPe for 48 h. Transporter protein content was then determined
byWestern-blot analysis. Left panel, a representative blot is shown for each transporter. Right panel, for each
transporter, data were quantified by densitometric analysis, normalised to Ponceau red staining and
expressed relative to transporter expression found in untreated cells, arbitrarily set at the value of 100% and
indicated by a dotted line; they are the means ± SEM of values from four independent assays. *, p<0.05
when compared to untreated cells (ANOVA followed by a Dunnett’s post-hoc test). (B) Two independent
populations of primary human hepatocytes were either untreated (control) or exposed to 25 μg/mL DEPe for
48 h. BCRP protein content was then determined byWestern-blot analysis.
doi:10.1371/journal.pone.0121232.g006
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Fig 7. Correlation of DEPe- and TCDD-induced changes of drug transporter mRNA expression. (A)
HepaRG cells were either untreated or exposed to 10 nM TCDD for 48 h. Drug transporter mRNA expression
was evaluated by RT-qPCR. Data are expressed as % of transporter expression found in control untreated
cells, arbitrarily set at the value of 100% and indicated by a dotted line; they are the means ± SEM of three
independent assays. *, p<0.05 when compared to control cells (ANOVA followed by a Dunnett’s post-hoc
test). (B) Drug transporters were ranked according to regulation of their mRNA expression in response to a
48-h treatment by 25 μg/mL DEPe or 10 nM TCDD. For this purpose, transporters were ranked for each
treatment from the most induced transporter to the most repressed, from data from Fig. 5B and Fig. 7A.
Correlation was analysed using the Spearman's rank correlation method. Spearman's rank coefficients (ρ)
and p values are provided on the top of the correlation graph.
doi:10.1371/journal.pone.0121232.g007
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method. As shown in Fig. 7B, the global effect of DEPe exposure on drug transporter expres-
sion in HepaRG cells was found to be highly correlated to that of TCDD.
Discussion
Previous studies have shown that environmental contaminants such as DEPs can regulate de-
toxifying enzymes in hepatic and extra-hepatic tissues [15, 16, 68]. The data reported in the
present work demonstrated that DEPe can also alter both activity and expression of human he-
patic drug transporters, thus confirming that detoxifying proteins constitute molecular targets
for DEPs.
DEPe was thus shown to strongly inhibit activity of the sinusoidal SLC transporters
OATP1B1, OATP1B3 and OATP2B1 and of the canalicular efflux pump MRP2. NTCP and
BCRP activities were also inhibited, but in a more moderate manner. These inhibitory effects
of DEPe towards these transporters were rather specific because the activities of other drug
transporters such as OCT1, MDR1/P-glycoprotein and BSEP, were not impacted. The mecha-
nism by which DEPe can inhibit OATP and MRP2 activity, remains to be determined; compet-
itive or non-competitive interactions with transporters [69] have likely to be considered. The
nature of the chemical(s) present in DEPe and responsible for the inhibition of transporter
activity remains also to be characterized. Involvement of PAHs found in relative notable con-
centrations in DEPe, such as phenanthrene, fluoranthene, benzo[b]fluoranthene, chrysene and
1-nitropyrene, can most likely be discarded. Indeed, these compounds used at a 10 μM concen-
tration failed to alter OATP- or MRP2-mediated transport. Because inhibitions of drug trans-
porter activity by chemicals occur through monotonic dose-dependent responses [70–72],
lower concentrations of PAHs (in the 0.01–1 nM range) found in DEPe solutions inhibiting
50% of OATP1B1 or MRP2 activity (Table 1) are most likely also inactive on OAPTP1B1 and
MRP2 activity. Similarly, involvement of PAH derivatives such as quinones is unlikely, owing
to the lack of effects of the 1,2-naphtoquinone towards OATP and MRP2 activity. Substrates
for OATPs and MRP2 are primarily organic anions and DEPe-contained chemical(s) blocking
them may therefore be hypothesized to also display anionic structural features at physiological
pH. The fact that the presence of an anionic group has been recently recognized as an impor-
tant chemical property for inhibition of OATP1B1 or OATP1B3 in quantitative structure activ-
ity relationship (QSAR) modeling [70] supports this hypothesis. Various other physico-
chemical properties required for the inhibition of OATPs or MRP2, including the value of
LogD, a high number of hydrogen bond acceptors, a large molecular volume and aromaticity
[70, 71], have also to be taken into account for the chemical structure of DEPe-contained
chemicals inhibiting OATPs- and/or MRP2-mediated transport. In addition, it should be kept
in mind that DEPe contains probably hundreds of organic chemicals and additive or synergic
effects of some of these chemicals may be involved in inhibition of transporter activity by
DEPe. Moreover, the role of putative metabolites formed from DEPe chemicals may have also
to be considered, even if some of the cell models used in the study, including OATP-transfected
CHO cells and hepatoma HuH-7 cells, are likely to poorly express xenobiotic metabolizing en-
zymes [34, 73].
In addition to directly inhibiting drug transporter activity, DEPe also modulates drug trans-
porter expression. The canalicular ABC efflux BCRP was thus induced by DEPe both at mRNA
and protein level in HepaRG cells. BCRP protein expression was also increased in primary
human hepatocytes exposed to DEPe. The sinusoidal ABC efflux pump MRP3 was similarly
up-regulated at mRNA level in HepaRG cells, but this up-regulation failed to reach significance
at protein level. Such a discrepancy may be due to the relative weak mRNA induction of this
transporter by DEPe or, alternatively, to a divergent regulation between transcriptional and
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post-transcriptional level, as already described for cytokine-mediated regulation of MRP3 [74].
In the same way, OATP2B1 was differently regulated by DEPe at mRNA (down-regulation)
and protein (no change) level. Other transporters whose mRNA expression was repressed by
DEPe exposure include various SLC sinusoidal transporters such as OATP1B3, OAT2, NTCP
and OCT1, and the canalicular bile salt efflux pump BSEP. By contrast, expression of the sinu-
soidal transporter OATP1B1 and of the canalicular transporters MDR1/P-glycoprotein and
MRP2 remained significantly unchanged, both at mRNA and protein levels. Overall, these
DEPe-induced changes in hepatic transporter expression correspond to a repression of most of
sinusoidal SLC uptake transporters and a preservation or an induction of ABC efflux pumps.
They may consequently be interpreted as a protective mechanism of hepatic cells exposed to
DEPe-containing chemicals, leading to decreased intracellular accumulation of potential toxic
chemicals through reduction of their uptake and enhancement of their efflux. BCRP induction
by DEPe likely illustrates this conclusion because BCRP up-regulation may be hypothesized to
result in enhanced efflux of toxic PAH metabolite substrates for this efflux pump [24].
AhR represents a well-recognized xenobiotic-sensing receptor activated by DEPs [8, 19]. It
was effectively stimulated in DEPe-exposed HepaRG cells, as demonstrated by up-regulation
of the reference AhR target genes CYP1A1, CYP1B1 and ALDH3A1. The AhR signaling path-
way is most likely implicated in DEPe-mediated regulations of drug transporters. Indeed, the
profile of transporter expression changes in DEPe-exposed HepaRG cells is highly correlated
to that resulting from treatment by the reference AhR agonist TCDD. Moreover, BCRP, which
is the most up-regulated transporter by DEPe, is known to be regulated by the AhR cascade
[24, 75]. In this context, various PAHs found in DEPe and known to be potent ligands for
AhR, such as chrysene and benzo[b]fluoranthene [76], may be hypothesized to be the main
DEPe-contained chemicals involved in transporter regulation.
The relevance of our in vitro findings to in vivo exposure to atmospheric DEPs constitutes
probably a key-point that has to be clarified. In this context, it is noteworthy that the concen-
trations of DEPe acting on OATP or MRP2 activity or on drug transporter expression levels,
that range from 1 μg/mL to 25 μg/mL, correspond to approximately 0.2 to 5 μg/cm2 equivalent
DEP dose according to previous conversions of in vitro DEPe/DEP dose to DEP dose/unit sur-
face area [56]. Importantly, such exposure levels are thought to be achieved in respiratory tracts
for subjects exposed to DEPs-containing atmospheres [56], thus underlining the fact that our
in vitro exposure conditions may be close to environmental exposure situations. Whether such
relevant pulmonary exposures to DEPs may result in hepatic concentrations of DEPe-con-
tained chemicals sufficient for acting on transporter expression or activity remains however to
characterize, but may be possible. Indeed, the passage across the pulmonary alveolar-capillary
barrier of ultrafine DEPs [10] and/or of some organic or inorganic DEP components as PAHs
[11] has already been demonstrated, thus bringing the proof of the concept that pulmonary ex-
posure to DEPs may result in internal exposure to DEPs-contained chemicals. This conclusion
is moreover supported by the development of various systemic effects after atmospheric expo-
sure to DEPs, including hepatic effects [12, 13].
Another key point that remains to be characterized corresponds to the potential conse-
quences of DEP effects on hepatic transporters. Inhibition of OATPs and MRP2 by DEPs may
impair hepatobiliary elimination of drug substrates for these transporters. The relevance of
such putative transporter-based interactions between pollutants like DEPs and drugs is howev-
er yet unknown [77], but may have to be considered, especially for OATP1B1 and OATP1B3.
Indeed, OATP1B1 and OATP1B3 handle many of the marketed drugs and are involved in
many clinically important drug-drug interactions [78]. Besides drugs, endogenous substrates
may also be impacted by the interaction of DEP-contained chemicals with transporters, which
may contribute to DEP toxicity. For example, MRP2 has been shown to efflux glutathione
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conjugates out of cells and by this way to protect them against oxidative stress [79]. Inhibition
of MRP2 by DEPe may therefore aggravate the well-established deleterious pro-oxidant effects
of DEPs [80]. In the same way, inhibition of OATPs and MRP2 by DEPe may alter in vivo
transport of steroid hormone substrates for these transporters, especially estrogens, which may
participate to endocrine disruption caused by DEPs [81]. OATPs and MRP2 are present not
only in the liver, but also in other tissues. For example, OATP2B1 is expressed at high levels in
the lung [82], the primary site affected by DEPs. It is also present, as well as MRP2, at the lumi-
nal pole of endothelial cells at the blood brain-barrier [83, 84], whose integrity is compromised
in response to pulmonary exposure to DEPs [85]. It may be therefore hypothesized that inhibi-
tion of OATP2B1 and MRP2 activity by DEPs may contribute to DEPe toxicity at these
anatomical sites.
In summary, DEPe, used at concentrations relevant to environmental exposure situations,
was shown to act as a bifunctional modulator of drug transporters, i.e., it inhibits in vitro
activity of hepatic drug transporters such as OATPs and MRP2 and alters expression of
some of them, notably BCRP. Such changes may contribute to systemic toxic effects of DEPs
through impairing hepatic transport of endogenous compounds or drug substrates of these
transporters.
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S1 Fig. Induction of CYP1B1 and ALDH3A1 mRNA expression by DEPe.Human highly-
differentiated HepaRG cells were either untreated (control) or exposed to 25 μg/mL DEPe for
48 h. CYP1B1 and ALDH3A1 mRNA expressions were analysed by RT-qPCR. Data are ex-
pressed in arbitrary units relative to 18S RNA content and are the means ± SEM of three inde-
pendent assays. , p<0.05 when compared to control cells (Student’s t-test).
(TIF)
S2 Fig. Induction of CYP1A1, CYP1B1 and ALDH3A1 mRNA expression by TCDD.
HepaRG cells were either untreated (control) or exposed to 10 nM TCDD for 48 h. CYP1A1,
CYP1B1 and ALDH3A1 mRNA expressions were evaluated by RT-qPCR. Data are expressed
in arbitrary units relative to 18S RNA content and are the means ± SEM of three independent
assays. , p<0.05 when compared to control cells (Student’s t-test).
(TIF)
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